OTC · BMYMP
Healthcare · Drug Manufacturers - General
$400.00
Down-$540.22 (-57.46%)
Updated Oct 12, 2026, 6:35 PM
SID Score
6.2/10
Composite research score
Smart Money
46/100
Neutral
Price performance · BMYMP
1M range · 0 trading sessions · Daily adjusted prices
BMYMP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BMYMP.
Company
Market Activity
Research & News
BMYMP research
Company profile and research snapshot.
BRISTOL-MYERS SQUIBB $2PR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Oct 7, 2026 | Morgan Stanley | Underweight | — |
| Oct 5, 2026 | Leerink Partners | Market Perform | — |
| Sep 16, 2026 | Piper Sandler | Overweight | — |
| Sep 10, 2026 | HSBC | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Mar 24, 2026
AQRâs Q4 2025 13F: $191B portfolio led by Nvidia plus Apple, Microsoft, Alphabet & Amazon, with selective diversification. See more details here.
Yahoo · Mar 9, 2026
Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.
Yahoo · Mar 9, 2026
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.
Yahoo · Mar 9, 2026
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Interpretive context generated from the platform’s current data sources.
Bristol-Myers Squibb's convertible preferred series BMYMP currently trades at $400.00 per share, per SID market data, reflecting a notably low-volatility profile with a beta of just 0.30, indicating the security moves significantly less than the broader market. The preferred shares exhibit extremely thin trading activity, with an average daily volume of approximately 5 shares, according to Massive/Polygon data. This illiquidity is characteristic of convertible preferred instruments that are typically held by long-term institutional investors rather than actively traded. The parent company maintains a substantial market capitalization of approximately $1.82 trillion across all share classes, positioning Bristol-Myers Squibb among the largest healthcare companies globally. The low beta suggests that BMYMP functions more as an income-oriented instrument than a growth vehicle, consistent with its preferred equity structure and the defensive nature of the healthcare sector in which the company operates.
BMYMP trades at a price-to-earnings ratio of 17.28, per SID market data, which sits within a reasonable range for a large-cap healthcare name. The PEG ratio of 0.90, according to SEC filings and derived estimates, suggests that the earnings multiple is well-supported by the company's expected growth trajectory, as a PEG below 1.0 traditionally indicates favorable valuation relative to growth. The price-to-book ratio stands at 5.62, reflecting a premium to tangible asset value that is typical for pharmaceutical companies with significant intangible assets including patents and pipeline intellectual property. Bristol-Myers Squibb's convertible preferred shares offer a dividend yield of 4.84%, providing meaningful income for holders. This yield level is competitive within the healthcare preferred equity space and reflects the hybrid nature of the instrument, which combines fixed-income characteristics with equity conversion optionality for investors seeking income with upside participation.
The composite smart money score for BMYMP stands at 46 out of 100 with a neutral signal, according to SID market data, indicating no strong directional conviction among sophisticated market participants. Breaking down the components, insider activity scores 12.5 out of 25, per SEC Form 4 filings, reflecting a balanced pattern of neither aggressive accumulation nor distribution by company executives and directors. Institutional ownership registers a score of 13.0 out of 25 based on 13F institutional filings, suggesting moderate but not overwhelming institutional interest in the convertible preferred shares. Dark pool activity scores notably lower at 8.5 out of 25, which aligns with the extremely low average trading volume of just 5 shares daily, indicating minimal off-exchange block trading activity. Congressional trading activity scores 12 out of 25, showing neither significant buying nor selling among tracked congressional portfolios. The overall neutral positioning suggests institutional holders are maintaining existing positions without meaningful new allocation changes to BMYMP at current price levels.
No recent earnings data specific to the BMYMP convertible preferred series is currently available in the reporting database. However, the parent company's financial health directly underpins the preferred dividend obligations, and the current P/E ratio of 17.28 and PEG ratio of 0.90, per SID market data, suggest the underlying business maintains solid earnings power relative to its valuation. The 4.84% dividend yield on the preferred shares, according to company earnings reports, requires sustained profitability and cash flow generation from Bristol-Myers Squibb's pharmaceutical operations to maintain ongoing distributions. As a healthcare sector entity, the company's earnings trajectory is typically influenced by patent expirations, pipeline developments, and drug pricing dynamics. Investors monitoring BMYMP should track the parent company's quarterly earnings releases for revenue trends and free cash flow metrics that determine the security and sustainability of preferred dividend payments going forward.
Wall Street coverage of Bristol-Myers Squibb reflects a predominantly cautious consensus, per SID consensus data. In October 2026, Cantor Fitzgerald maintained a Neutral rating, while Morgan Stanley reiterated an Underweight stance, according to Wall Street analyst reports. Notably, Leerink Partners downgraded the stock to Market Perform from Outperform in early October 2026, representing a meaningful shift toward a more conservative outlook. In September 2026, Piper Sandler reiterated an Overweight rating, standing as the most constructive voice among recent coverage updates. HSBC maintained a Hold rating in September 2026, adding to the neutral-to-cautious tone. Of the five most recent analyst actions, only one carries a bullish equivalent rating, three hold neutral or market-perform positions, and one maintains an underweight recommendation. This distribution suggests that the analyst community views Bristol-Myers Squibb as fairly valued at current levels, with limited near-term catalysts to drive significant re-rating of the preferred shares.
The latest Smart Investors Daily articles mentioning BMYMP.
